Is Invo Bioscience Inc (OTCMKTS:IVOB) Worth The Hype?

Invo Bioscience Inc (OTCMKTS:IVOB) exploded up the charts for two sessions in a row after an announcement that the FDA has given it clearance for its INVOcell device.

It is rare to see a ticker behave in such a manner – and that’s not because OTC Markets Pharmaceutical tickers don’t get volatile when news comes out. No, what we mean is that it is rare to see an OTC Markets company actually receive FDA approval – news of that caliber is certainly not something you see every day, and is worth the praise and the excitement.

Unfortunately, nothing else about IVOB is really worth the hype. Or rather, it may be more accurate to say that we don’t know if IVOB has anything to its name worth the excitement, because it has not filed a financial report for more than FOUR YEARS.

So while technically IVOB may have something to its name, it is just as likely that it doesn’t. Its future success depends on its preparedness to capitalize on the market. Well, what if it isn’t ready? It could well have next to nothing to its name – who knows?

On another note, as all seasoned OTC Markets investors know by now, if there is one thing that most OTC Markets pharmaceutical penny stocks have in common, it is their tendency towards toxic funding.

There are barely any companies in the branch that have not signed questionable agreements at one point or another, and truth be told, in light of the fact that IVOB has already done so in the past, it seems likely that there is still some debt looming over investor value now.

Again, it is too bad we don’t know anything else about the company – otherwise it would have been easy to make a pretty accurate assessment of whether or not it is worth investing in IVOB stock. However, as it is now, committing to IVOB stock is nothing less than a blind gamble – because if the company DOES have toxic debt, or even notes that convert at prices from previous market highs. Even if the notes are not severely discounted, a dumping of those could obliterate its market cap.

Even the boldest investors should definitely consider that when deciding whether or not to play IVOB.